CN100408591C - 嘧啶核苷衍生物的晶形 - Google Patents

嘧啶核苷衍生物的晶形 Download PDF

Info

Publication number
CN100408591C
CN100408591C CNB028079337A CN02807933A CN100408591C CN 100408591 C CN100408591 C CN 100408591C CN B028079337 A CNB028079337 A CN B028079337A CN 02807933 A CN02807933 A CN 02807933A CN 100408591 C CN100408591 C CN 100408591C
Authority
CN
China
Prior art keywords
crystal
compound
crystalline form
obtains
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028079337A
Other languages
English (en)
Chinese (zh)
Other versions
CN1501939A (zh
Inventor
泷田崇
大塚惠一
沼上英治
原岛达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of CN1501939A publication Critical patent/CN1501939A/zh
Application granted granted Critical
Publication of CN100408591C publication Critical patent/CN100408591C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB028079337A 2001-02-09 2002-02-06 嘧啶核苷衍生物的晶形 Expired - Lifetime CN100408591C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33128/2001 2001-02-09
JP2001033128 2001-02-09

Publications (2)

Publication Number Publication Date
CN1501939A CN1501939A (zh) 2004-06-02
CN100408591C true CN100408591C (zh) 2008-08-06

Family

ID=18896929

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028079337A Expired - Lifetime CN100408591C (zh) 2001-02-09 2002-02-06 嘧啶核苷衍生物的晶形

Country Status (21)

Country Link
EP (1) EP1364959B1 (enExample)
JP (2) JP3748536B2 (enExample)
KR (1) KR100679904B1 (enExample)
CN (1) CN100408591C (enExample)
AT (1) ATE361929T1 (enExample)
AU (1) AU2002230164B2 (enExample)
BR (2) BR0207102A (enExample)
CA (1) CA2437994C (enExample)
CY (1) CY1106685T1 (enExample)
CZ (1) CZ303241B6 (enExample)
DE (1) DE60220024T2 (enExample)
DK (1) DK1364959T3 (enExample)
ES (1) ES2286237T3 (enExample)
HU (1) HU229294B1 (enExample)
IL (2) IL157216A0 (enExample)
MX (1) MXPA03007123A (enExample)
NZ (1) NZ527393A (enExample)
PT (1) PT1364959E (enExample)
RU (1) RU2256666C2 (enExample)
WO (1) WO2002064609A1 (enExample)
ZA (1) ZA200306121B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019149A1 (en) 1999-09-02 2001-03-15 Ibiden Co., Ltd. Printed wiring board and method of producing the same and capacitor to be contained in printed wiring board
WO2001019148A1 (fr) 1999-09-02 2001-03-15 Ibiden Co., Ltd. Carte de circuit imprime et procede de fabrication associe
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
JP5066737B2 (ja) * 2007-04-06 2012-11-07 大鵬薬品工業株式会社 シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤
US8124593B2 (en) 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
GB0808357D0 (en) * 2008-05-08 2008-06-18 Cyclacel Ltd Process
US8530445B2 (en) 2008-06-09 2013-09-10 Cyclacel Limited Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine
US10226478B2 (en) 2011-04-14 2019-03-12 Cyclacel Limited Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
ES2880109T3 (es) 2012-03-15 2021-11-23 Celgene Car Llc Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
KR102629310B1 (ko) 2015-03-09 2024-01-24 더블유.알. 그레이스 앤드 캄파니-콘. 니코틴아미드 리보사이드의 결정 형태
CN112020363A (zh) 2017-12-22 2020-12-01 益力舒健康公司 烟酰胺核苷氯化物的结晶形式

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072686A (zh) * 1991-09-30 1993-06-02 三共株式会社 具有抗肿瘤活性的嘧啶核苷衍生物及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072686A (zh) * 1991-09-30 1993-06-02 三共株式会社 具有抗肿瘤活性的嘧啶核苷衍生物及其制备方法和用途

Also Published As

Publication number Publication date
PT1364959E (pt) 2007-07-23
AU2002230164B2 (en) 2005-04-07
HUP0303159A3 (en) 2007-06-28
HUP0303159A2 (hu) 2003-12-29
EP1364959A1 (en) 2003-11-26
JP2002308895A (ja) 2002-10-23
ZA200306121B (en) 2005-01-26
BRPI0207102A8 (pt) 2018-02-27
CZ20032111A3 (cs) 2003-12-17
DE60220024D1 (en) 2007-06-21
ES2286237T3 (es) 2007-12-01
BR0207102A (pt) 2004-01-27
JP2006008699A (ja) 2006-01-12
DK1364959T3 (da) 2007-06-04
RU2003124648A (ru) 2005-02-27
JP4356998B2 (ja) 2009-11-04
KR20030081424A (ko) 2003-10-17
DE60220024T2 (de) 2007-11-22
KR100679904B1 (ko) 2007-02-07
CA2437994A1 (en) 2002-08-22
CY1106685T1 (el) 2012-05-23
HU229294B1 (en) 2013-10-28
ATE361929T1 (de) 2007-06-15
IL157216A (en) 2008-03-20
EP1364959B1 (en) 2007-05-09
CN1501939A (zh) 2004-06-02
RU2256666C2 (ru) 2005-07-20
EP1364959A4 (en) 2004-03-24
CA2437994C (en) 2011-05-17
IL157216A0 (en) 2004-02-19
WO2002064609A1 (en) 2002-08-22
NZ527393A (en) 2004-07-30
CZ303241B6 (cs) 2012-06-13
JP3748536B2 (ja) 2006-02-22
MXPA03007123A (es) 2003-11-18

Similar Documents

Publication Publication Date Title
CN114929704B (zh) 含螺环的喹唑啉化合物
CN100408591C (zh) 嘧啶核苷衍生物的晶形
EP4484438A1 (en) POLYMORPHIC FORM OF REDUCED ß-NICOTINAMIDE MONONUCLEOTIDE DISODIUM SALT, AND PREPARATION METHOD THEREFOR AND USE THEREOF
CN107531646B (zh) 尿嘧啶化合物的结晶
KR20010099806A (ko) 아지트로마이신의 에탄올레이트, 이것의 제조 방법 및약학 조성물
CN101597272B (zh) 艾拉莫德的钾盐化合物,其制备方法和药物应用
CN101325958A (zh) 结晶态来他替尼(lestaurtinib)水合物和结晶态来他替尼半水合半乙腈化物和结晶态来他替尼半水合半四氢呋喃化物
WO2022228578A1 (en) Pyrimidinylaminobenzenes for lung cancer treatment
CA3059455A1 (en) Compound of eoc315 mod.i crystal form and preparation method therefor
WO2021139797A1 (zh) 恩曲替尼晶型及其制备方法
CN1324354A (zh) 玻璃状己知缓激肽拮抗剂
CN101665449A (zh) 他米巴罗汀的水溶性前药及其制备方法与应用
CN118290384A (zh) 大豆苷元与哌嗪共晶物及制备方法和其组合物与用途
JP2025527161A (ja) 置換されたピラゾロ［１，５－ａ］ピリミジン－７－アミン誘導体の薬学的に許容される塩および多形体、ならびにその使用
CA3068357A1 (en) New salt of n-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation and formulations containing it
AU732408B2 (en) Nucleosides
EP3007700B1 (en) New polymorphic forms of icotinib phosphate and uses thereof
CN109846873B (zh) 一种抗肿瘤药物组合物
CN113801021A (zh) 绿原酸钠水合物及其应用
CN117263982B (zh) 含氮芳基磷氧化物衍生物的晶型及其制备方法和应用
CN109528664B (zh) 含乌苯美司-抗肿瘤药物协同前药衍生物的冻干粉剂及其制备方法
CN109646429B (zh) 一种含乌苯美司的前药衍生物的固体剂型及其制备方法
CN112047990B (zh) 阿糖胞苷前药mb07133晶型及其应用
EP4234557A1 (en) Salt of nucleoside analog and crystal form thereof, pharmaceutical composition and use
CN104045614A (zh) (1s)-1-[4-氯-3-(4-乙氧基苄基)苯基]-1,6-二脱氧-d-葡萄糖的晶型c及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20080806

CX01 Expiry of patent term